Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Considers Easing Industry Burden In AF Ablation Catheter Trial Design

This article was originally published in The Gray Sheet

Executive Summary

FDA may be willing to accept a reduction of symptoms as the primary endpoint for atrial fibrillation ablation catheter clinical trials, according to CDRH Cardiac Electrophysiology & Monitoring Devices Branch Medical Officer Randall Brockman, MD

You may also be interested in...



HRS A-Fib Ablation Consensus Statement Offers Clinical Trial Advice

A new expert 1consensus statement on ablation of atrial fibrillation, created by a Heart Rhythm Society task force, includes 21 specific recommendations for the design and conduct of clinical trials of AF ablation devices

HRS A-Fib Ablation Consensus Statement Offers Clinical Trial Advice

A new expert 1consensus statement on ablation of atrial fibrillation, created by a Heart Rhythm Society task force, includes 21 specific recommendations for the design and conduct of clinical trials of AF ablation devices

FDA Dispute Panel Rebuffs Cardima’s Catheter A-Fib Claims

An FDA dispute resolution body all but halted Cardima's chances to turn around the fortunes of its Revelation Tx microcatheter NavAblator ablation system April 19, voting 5-0 not to recommend approval of the product

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023129

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel